Invesco
TERN

Invesco’s Terns Pharmaceuticals TERN Stock Holding History

Invesco’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1M Sell
304,487
-301,760
-50% -$12.4M ﹤0.01% 1574
2025
Q4 		$24.5M Buy
606,247
+128,573
+27% +$2.97M ﹤0.01% 1357
2025
Q3 		$3.59M Buy
477,674
+383,140
+405% +$2.45M ﹤0.01% 2379
2025
Q2 		$353K Buy
94,534
+36,189
+62% +$113K ﹤0.01% 3309
2025
Q1 		$161K Buy
58,345
+34,945
+149% +$143K ﹤0.01% 3557
2024
Q4 		$130K Buy
23,400
+2,753
+13% +$18.6K ﹤0.01% 3593
2024
Q3 		$172K Sell
20,647
-654
-3% -$5.38K ﹤0.01% 3546
2024
Q2 		$145K Sell
21,301
-862
-4% -$5.22K ﹤0.01% 3701
2024
Q1 		$145K Buy
22,163
+372
+2% +$2.43K ﹤0.01% 3700
2023
Q4 		$141K Sell
21,791
-19,159
-47% -$101K ﹤0.01% 3631
2023
Q3 		$206K Buy
40,950
+18,955
+86% +$120K ﹤0.01% 3584
2023
Q2 		$192K Sell
21,995
-552,182
-96% -$6.44M ﹤0.01% 3621
2023
Q1 		$6.8M Buy
+574,177
New +$5.49M ﹤0.01% 2071

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Invesco's TERN Position: Q1 2026 in Review

Invesco reduced its Terns Pharmaceuticals (TERN) stake by 50% in Q1 2026, selling an estimated $12.4M and leaving 304,487 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Invesco first reported a position in TERN in Q1 2023 and has held it in 13 quarters since. The position peaked at $24.5M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Invesco held 304,487 shares of Terns Pharmaceuticals worth $16.1M as of Q1 2026.
  • Invesco sold 301,760 Terns Pharmaceuticals shares in Q1 2026, an estimated $12.4M.
  • Terns Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1574 holding.
  • Invesco first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Invesco's Terns Pharmaceuticals position peaked at $24.5M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.